- Home
- AMBQ vs VIR Comparison
AMBQ vs VIR Comparison
Compare AMBQ & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBQ
- VIR
- Stock Information
- Founded
- AMBQ 2010
- VIR 2016
- Country
- AMBQ United States
- VIR United States
- Employees
- AMBQ N/A
- VIR N/A
- Industry
- AMBQ Semiconductors
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- AMBQ Technology
- VIR Health Care
- Exchange
- AMBQ Nasdaq
- VIR Nasdaq
- Market Cap
- AMBQ 673.1M
- VIR 706.4M
- IPO Year
- AMBQ 2025
- VIR 2019
- Fundamental
- Price
- AMBQ $30.32
- VIR $5.73
- Analyst Decision
- AMBQ Buy
- VIR Strong Buy
- Analyst Count
- AMBQ 4
- VIR 11
- Target Price
- AMBQ $43.75
- VIR $25.73
- AVG Volume (30 Days)
- AMBQ 259.2K
- VIR 1.1M
- Earning Date
- AMBQ 11-14-2025
- VIR 10-30-2025
- Dividend Yield
- AMBQ N/A
- VIR N/A
- EPS Growth
- AMBQ N/A
- VIR N/A
- EPS
- AMBQ N/A
- VIR N/A
- Revenue
- AMBQ $74,210,000.00
- VIR $19,000,000.00
- Revenue This Year
- AMBQ N/A
- VIR N/A
- Revenue Next Year
- AMBQ $25.34
- VIR $11.08
- P/E Ratio
- AMBQ N/A
- VIR N/A
- Revenue Growth
- AMBQ N/A
- VIR N/A
- 52 Week Low
- AMBQ $28.61
- VIR $4.16
- 52 Week High
- AMBQ $51.76
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- AMBQ N/A
- VIR 64.05
- Support Level
- AMBQ N/A
- VIR $5.14
- Resistance Level
- AMBQ N/A
- VIR $6.00
- Average True Range (ATR)
- AMBQ 0.00
- VIR 0.29
- MACD
- AMBQ 0.00
- VIR 0.06
- Stochastic Oscillator
- AMBQ 0.00
- VIR 78.40
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.